## Rafael SimÃ<sup>3</sup>

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7408189/publications.pdf

Version: 2024-02-01

327 papers 16,779 citations

63 h-index 22166 113 g-index

340 all docs

340 docs citations

340 times ranked 17017 citing authors

#	Article	IF	Citations
1	ERM Complex, A Therapeutic Target for Vascular Leakage Induced by Diabetes. Current Medicinal Chemistry, 2022, 29, 2189-2199.	2.4	2
2	Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study. Diabetes, 2022, 71, 315-320.	0.6	19
3	The Impact of Bariatric Surgery on the Muscle Mass in Patients with Obesity: 2-Year Follow-up. Obesity Surgery, 2022, 32, 625-633.	2.1	18
4	Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. Trends in Endocrinology and Metabolism, 2022, 33, 50-71.	7.1	34
5	Association Between Diabetic Retinopathy, Brain Structural Abnormalities, and Cognitive Impairment for Accumulated Evidence in Observational Studies. American Journal of Ophthalmology, 2022, 239, 37-53.	3.3	12
6	Diabetic Retinopathy Predicts Risk of Alzheimer's Disease: A Danish Registry-Based Nationwide Cohort Study. Journal of Alzheimer's Disease, 2022, 86, 451-460.	2.6	11
7	Phenotyping Type 2 Diabetes in Terms of Myocardial Insulin Resistance and Its Potential Cardiovascular Consequences: A New Strategy Based on 18F-FDG PET/CT. Journal of Personalized Medicine, 2022, 12, 30.	2.5	2
8	Deep Learning of Retinal Imaging: A Useful Tool for Coronary Artery Calcium Score Prediction in Diabetic Patients. Applied Sciences (Switzerland), 2022, 12, 1401.	2.5	7
9	Minimum Effective Dose of DPP-4 Inhibitors for Treating Early Stages of Diabetic Retinopathy in an Experimental Model. Biomedicines, 2022, 10, 465.	3.2	3
10	Prediabetes Is Associated with Increased Prevalence of Sleep-Disordered Breathing. Journal of Clinical Medicine, 2022, 11, 1413.	2.4	5
11	Diabetic Retinopathy: Role of Neurodegeneration and Therapeutic Perspectives. Asia-Pacific Journal of Ophthalmology, 2022, 11, 160-167.	2.5	14
12	Neuronal Dysfunction Is Linked to the Famine-Associated Risk of Proliferative Retinopathy in Patients With Type 2 Diabetes. Frontiers in Neuroscience, 2022, 16, .	2.8	1
13	Usefulness of Muscle Ultrasound to Study Sarcopenic Obesity: A Pilot Case-Control Study. Journal of Clinical Medicine, 2022, 11, 2886.	2.4	3
14	Advanced Glycations End Products in the Skin as Biomarkers of Cardiovascular Risk in Type 2 Diabetes. International Journal of Molecular Sciences, 2022, 23, 6234.	4.1	4
15	Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D. Diabetes Therapy, 2022, 13, 35-49.	2.5	5
16	State-of-the-Art Research on Diabetic Retinopathy. Journal of Clinical Medicine, 2022, 11, 3790.	2.4	0
17	Bidirectional relationship between diabetes and pulmonary function: a systematic review and meta-analysis. Diabetes and Metabolism, 2021, 47, 101186.	2.9	12
18	HOMA-IR in acromegaly: a systematic review and meta-analysis. Pituitary, 2021, 24, 146-158.	2.9	10

#	Article	IF	CITATIONS
19	Acromegaly: Diabetes and HOMA-IR. EndocrinologÃa Diabetes Y Nutrición (English Ed ), 2021, 68, 1-2.	0.2	O
20	GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice. International Journal of Molecular Sciences, 2021, 22, 415.	4.1	7
21	Impact of Intensive Glucose Control on Brain Health: Meta-Analysis of Cumulative Data from 16,584 Patients with Type 2 Diabetes Mellitus. Diabetes Therapy, 2021, 12, 765-779.	2.5	15
22	Spectrum of thyroid dysfunction and dementia: a dose–response meta-analysis of 344,248 individuals from cohort studies. Endocrine Connections, 2021, 10, 410-421.	1.9	12
23	Usefulness of skin advanced glycation end products to predict coronary artery calcium score in patients with type 2 diabetes. Acta Diabetologica, 2021, 58, 1403-1412.	2.5	6
24	Cardiac-Specific Overexpression of ERRÎ <sup>3</sup> in Mice Induces Severe Heart Dysfunction and Early Lethality. International Journal of Molecular Sciences, 2021, 22, 8047.	4.1	7
25	The Gaze Fixation Assessed by Microperimetry: A Useful Tool for the Monitoring of the Cognitive Function in Patients with Type 2 Diabetes. Journal of Personalized Medicine, 2021, 11, 698.	2.5	4
26	Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes. Biomedicines, 2021, 9, 926.	3.2	12
27	Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy. Pharmaceutics, 2021, 13, 1320.	4.5	30
28	Evaluation of Resting Energy Expenditure in Subjects with Severe Obesity and Its Evolution After Bariatric Surgery. Obesity Surgery, 2021, 31, 4347-4355.	2.1	15
29	Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. European Journal of Endocrinology, 2021, 185, 587-595.	3.7	9
30	Relationship between obesity and structural brain abnormality: Accumulated evidence from observational studies. Ageing Research Reviews, 2021, 71, 101445.	10.9	18
31	Relationship between Central Obesity and the incidence of Cognitive Impairment and Dementia from Cohort Studies Involving 5,060,687 Participants. Neuroscience and Biobehavioral Reviews, 2021, 130, 301-313.	6.1	43
32	Diabetes y HOMA-IR en la acromegalia. Endocrinologia, Diabetes Y NutriciÓn, 2021, 68, 1-2.	0.3	1
33	A Clinical-Genetic Score for Predicting Weight Loss after Bariatric Surgery: The OBEGEN Study. Journal of Personalized Medicine, 2021, 11, 1040.	2.5	13
34	Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications. International Journal of Molecular Sciences, 2021, 22, 11247.	4.1	5
35	Decreased endostatin in db/db retinas is associated with optic disc intravitreal vascularization. Experimental Eye Research, 2021, 212, 108801.	2.6	3
36	Neuromodulation Induced by Sitagliptin: A New Strategy for Treating Diabetic Retinopathy. Biomedicines, 2021, 9, 1772.	3.2	6

#	Article	IF	CITATIONS
37	Diabetic Retinopathy and Skin Tissue Advanced Glycation End Products Are Biomarkers of Cardiovascular Events in Type 2 Diabetic Patients. Journal of Personalized Medicine, 2021, 11, 1344.	2.5	2
38	The Association Between Diabetes Mellitus and Risk of Sarcopenia: Accumulated Evidences From Observational Studies. Frontiers in Endocrinology, 2021, 12, 782391.	3.5	41
39	Combining metabolic profiling of plasma and faeces as a fingerprint of insulin resistance in obesity. Clinical Nutrition, 2020, 39, 2292-2300.	5.0	9
40	Is it time to change the management of permanent postsurgical hypoparathyroidism?. Endocrinologia, Diabetes Y NutriciÓn, 2020, 67, 1-3.	0.3	0
41	Neuropathic damage in the diabetic eye: clinical implications. Current Opinion in Pharmacology, 2020, 55, 1-7.	3.5	3
42	Is it time to change the management of permanent postsurgical hypoparathyroidism?. Endocrinolog $\tilde{A}$ a Diabetes Y Nutrici $\tilde{A}$ 3n (English Ed ), 2020, 67, 1-3.	0.2	0
43	Caffeine Upregulates Hepatic Sex Hormoneâ€Binding Globulin Production by Increasing Adiponectin Through AKT/FOXO1 Pathway in White Adipose Tissue. Molecular Nutrition and Food Research, 2020, 64, e1901253.	3.3	4
44	Sex hormone-binding globulin overexpression protects against high-fat diet-induced obesity in transgenic male mice. Journal of Nutritional Biochemistry, 2020, 85, 108480.	4.2	16
45	Utility of Insulin Resistance in Estimating Cardiovascular Risk in Subjects with Type 1 Diabetes According to the Scores of the Steno Type 1 Risk Engine. Journal of Clinical Medicine, 2020, 9, 2192.	2.4	13
46	Effect of Topical Administration of Somatostatin on Retinal Inflammation and Neurodegeneration in an Experimental Model of Diabetes. Journal of Clinical Medicine, 2020, 9, 2579.	2.4	15
47	Effect of Type 2 Diabetes Mellitus on the Hypoxia-Inducible Factor 1-Alpha Expression. Is There a Relationship with the Clock Genes?. Journal of Clinical Medicine, 2020, 9, 2632.	2.4	4
48	Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain. Journal of Clinical Medicine, 2020, 9, 2726.	2.4	4
49	Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities: Involvement of Oxidative Stress. Antioxidants, 2020, 9, 846.	5.1	21
50	Non-linear association between diabetes mellitus and pulmonary function: a population-based study. Respiratory Research, 2020, 21, 292.	3.6	13
51	Looking for solutions to lung dysfunction in type 2 diabetes. Annals of Translational Medicine, 2020, 8, 521-521.	1.7	1
52	A Translational In Vivo and In Vitro Metabolomic Study Reveals Altered Metabolic Pathways in Red Blood Cells of Type 2 Diabetes. Journal of Clinical Medicine, 2020, 9, 1619.	2.4	15
53	Diabetic retinopathy: looking beyond the eyes. Diabetologia, 2020, 63, 1662-1664.	6.3	11
54	Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic. Scientific Reports, 2020, 10, 1580.	3.3	22

#	Article	IF	Citations
55	Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes and Endocrinology, the, 2020, 8, 337-347.	11.4	288
56	The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial. Journal of Clinical Medicine, 2020, 9, 1233.	2.4	10
57	Effect of Subcutaneous Insulin on Spirometric Maneuvers in Patients with Type 1 Diabetes: A Case-Control Study. Journal of Clinical Medicine, 2020, 9, 1249.	2.4	2
58	Alteration of the Mitochondrial Effects of Ceria Nanoparticles by Gold: An Approach for the Mitochondrial Modulation of Cells Based on Nanomedicine. Nanomaterials, 2020, 10, 744.	4.1	9
59	Effect of Glucose Improvement on Nocturnal Sleep Breathing Parameters in Patients with Type 2 Diabetes: The Candy Dreams Study. Journal of Clinical Medicine, 2020, 9, 1022.	2.4	7
60	Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis. Metabolism: Clinical and Experimental, 2020, 109, 154265.	3.4	64
61	Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurology, The, 2020, 19, 699-710.	10.2	96
62	The ERM Complex: A New Player Involved in Diabetes-induced Vascular Leakage. Current Medicinal Chemistry, 2020, 27, 3012-3022.	2.4	4
63	Genetic Testing to Predict Weight Loss and Diabetes Remission and Long-Term Sustainability after Bariatric Surgery: A Pilot Study. Journal of Clinical Medicine, 2019, 8, 964.	2.4	13
64	SOCS1-Derived Peptide Administered by Eye Drops Prevents Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes. International Journal of Molecular Sciences, 2019, 20, 3615.	4.1	25
65	Usefulness of Liquid Biopsy Biomarkers from Aqueous Humor in Predicting Anti-VEGF Response in Diabetic Macular Edema: Results of a Pilot Study. Journal of Clinical Medicine, 2019, 8, 1841.	2.4	25
66	Characteristics of atheromatosis in the prediabetes stage: a cross-sectional investigation of the ILERVAS project. Cardiovascular Diabetology, 2019, 18, 154.	6.8	17
67	Sympathetic Hyperactivity and Sleep Disorders in Individuals With Type 2 Diabetes. Frontiers in Endocrinology, 2019, 10, 752.	3.5	5
68	Arterial stiffness is highly correlated with the scores obtained from the Steno Type 1 Risk Engine in subjects with T1DM. PLoS ONE, 2019, 14, e0220206.	2.5	23
69	Assessment of Inner Retinal Layers and Choroidal Thickness in Type 1 Diabetes Mellitus: A Cross-Sectional Study. Journal of Clinical Medicine, 2019, 8, 1412.	2.4	21
70	$\hat{\Gamma}$ Opioid Receptor Agonism Preserves the Retinal Pigmented Epithelial Cell Tight Junctions and Ameliorates the Retinopathy in Experimental Diabetes. , 2019, 60, 3842.		7
71	Metabolic Fingerprint of Acromegaly and its Potential Usefulness in Clinical Practice. Journal of Clinical Medicine, 2019, 8, 1549.	2.4	12
72	Adipocyte MTERF4 regulates non-shivering adaptive thermogenesis and sympathetic-dependent glucose homeostasis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1298-1312.	3.8	5

#	Article	IF	Citations
73	Effect of Glucose Improvement on Spirometric Maneuvers in Patients With Type 2 Diabetes: The Sweet Breath Study. Diabetes Care, 2019, 42, 617-624.	8.6	15
74	Visual impairment in aging and cognitive decline: experience in a Memory Clinic. Scientific Reports, 2019, 9, 8698.	3.3	32
75	Diabetic Retinopathy in the Context of Patients with Diabetes. Ophthalmic Research, 2019, 62, 211-217.	1.9	130
76	Cytoskeletal transgelin 2 contributes to genderâ€dependent adipose tissue expandability and immune function. FASEB Journal, 2019, 33, 9656-9671.	0.5	6
77	Topical Treatment With Brimonidine and Somatostatin Causes Retinal Vascular Dilation in Patients With Early Diabetic Retinopathy From the EUROCONDOR. , 2019, 60, 2257.		18
78	The MOPEAD project: Advancing patient engagement for the detection of "hidden―undiagnosed cases of Alzheimer's disease in the community. , 2019, 15, 828-839.		20
79	Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project. Journal of Atherosclerosis and Thrombosis, 2019, 26, 879-889.	2.0	9
80	Lung function measurements in the prediabetes stage: data from the ILERVAS Project. Acta Diabetologica, 2019, 56, 1005-1012.	2.5	11
81	Glutamate interactions with obesity, insulin resistance, cognition and gut microbiota composition. Acta Diabetologica, 2019, 56, 569-579.	2.5	49
82	Sex Hormone–Binding Globulin Expression Correlates With Acetyl-Coenzyme A Carboxylase and Triglyceride Content in Human Liver. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1500-1507.	3.6	26
83	New Insights into the Mechanisms of Action of Topical Administration of GLP-1 in an Experimental Model of Diabetic Retinopathy. Journal of Clinical Medicine, 2019, 8, 339.	2.4	34
84	Differences in the cluster of depressive symptoms between subjects with type 2 diabetes and individuals with a major depressive disorder and without diabetes. Journal of Endocrinological Investigation, 2019, 42, 881-888.	3.3	9
85	Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study. BMJ Open Diabetes Research and Care, 2019, 7, e000845.	2.8	24
86	Retinal Microperimetry: A Useful Tool for Detecting Insulin Resistance-Related Cognitive Impairment in Morbid Obesity. Journal of Clinical Medicine, 2019, 8, 2181.	2.4	5
87	Diabetische Retinopathie bei Patienten mit Diabetes mellitus. Karger Kompass Ophthalmologie, 2019, 5, 157-162.	0.0	0
88	Comment on: "Glucagonâ€like peptideâ€1 receptor expression in the human eyeâ€. Diabetes, Obesity and Metabolism, 2019, 21, 446-447.	4.4	1
89	Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial. Diabetes, 2019, 68, 457-463.	0.6	69
90	Usefulness of Eye Fixation Assessment for Identifying Type 2 Diabetic Subjects at Risk of Dementia. Journal of Clinical Medicine, 2019, 8, 59.	2.4	15

#	Article	IF	Citations
91	Calorie restriction prevents dietâ€induced insulin resistance independently of PGCâ€1â€driven mitochondrial biogenesis in white adipose tissue. FASEB Journal, 2019, 33, 2343-2358.	0.5	16
92	Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. Diabetes, Obesity and Metabolism, 2019, 21, 467-478.	4.4	110
93	Subcutaneous advanced glycation end-products and lung function according to glucose abnormalities: The ILERVAS Project. Diabetes and Metabolism, 2019, 45, 595-598.	2.9	12
94	DIALCAT: Diabetes as an accelerator of cognitive impairment and Alzheimer's disease, comprehensive approach and adherence to treatment. Computacion Y Sistemas, 2019, 23, .	0.3	1
95	Somatostatin and diabetic retinopathy: an evolving story. Endocrine, 2018, 60, 1-3.	2.3	13
96	Response to oral sucrosomial iron supplementation in patients undergoing bariatric surgery. The BARI-FER study. Endocrinologia, Diabetes Y NutriciÓn, 2018, 65, 17-20.	0.3	16
97	Silymarin prevents diabetes-induced hyperpermeability in human retinal endothelial cells. Endocrinologia, Diabetes Y NutriciÓn, 2018, 65, 200-205.	0.3	11
98	A compartmentalized microfluidic chip with crisscross microgrooves and electrophysiological electrodes for modeling the blood–retinal barrier. Lab on A Chip, 2018, 18, 95-105.	6.0	61
99	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity and Metabolism, 2018, 20, 889-897.	4.4	173
100	Decreased TLR3 in Hyperplastic Adipose Tissue, Blood and Inflamed Adipocytes is Related to Metabolic Inflammation. Cellular Physiology and Biochemistry, 2018, 51, 1051-1068.	1.6	14
101	Topical Administration of Bosentan Prevents Retinal Neurodegeneration in Experimental Diabetes. International Journal of Molecular Sciences, 2018, 19, 3578.	4.1	21
102	Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease. Scientific Reports, 2018, 8, 16345.	3.3	52
103	Assessment of advanced glycation end-products as a biomarker of diabetic outcomes. Endocrinologia, Diabetes Y Nutriciēn, 2018, 65, 540-545.	0.3	19
104	Silymarin prevents diabetes-induced hyperpermeability in human retinal endothelial cells. EndocrinologÃa Diabetes Y Nutrición (English Ed ), 2018, 65, 200-205.	0.2	0
105	Neurodegeneration in diabetic retinopathy: does it really matter?. Diabetologia, 2018, 61, 1902-1912.	6.3	358
106	Metabolic fingerprint of insulin resistance in human polymorphonuclear leucocytes. PLoS ONE, 2018, 13, e0199351.	2.5	9
107	Effects of Liposomal Formulation of Citicoline in Experimental Diabetes-Induced Retinal Neurodegeneration. International Journal of Molecular Sciences, 2018, 19, 2458.	4.1	22
108	Proteomic Analysis of Early Diabetic Retinopathy Reveals Mediators of Neurodegenerative Brain Diseases., 2018, 59, 2264.		91

#	Article	IF	Citations
109	Liquid Biopsy of Vitreous Reveals an Abundant Vesicle Population Consistent With the Size and Morphology of Exosomes. Translational Vision Science and Technology, 2018, 7, 6.	2.2	86
110	Sleep biosignature of Type 2 diabetes: a case–control study. Diabetic Medicine, 2017, 34, 79-85.	2.3	9
111	Cognitive impairment and dementia: a new emerging complication of type 2 diabetes—The diabetologist's perspective. Acta Diabetologica, 2017, 54, 417-424.	2.5	127
112	Development of a Normative Database for Multifocal Electroretinography in the Context of a Multicenter Clinical Trial. Ophthalmic Research, 2017, 57, 107-117.	1.9	12
113	Type 2 diabetes is an independent risk factor for dementia conversion in patients with mild cognitive impairment. Journal of Diabetes and Its Complications, 2017, 31, 1272-1274.	2.3	54
114	Type 2 diabetes, risk of sleep apnea-hypopnea syndrome, and quality of life associated to sleep breathing disorders. EndocrinologÃa Diabetes Y Nutrición (English Ed ), 2017, 64, 174-176.	0.2	0
115	GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?. Diabetes, 2017, 66, 1453-1460.	0.6	55
116	Type 2 diabetes, risk of sleep apnea-hypopnea syndrome, and quality of life associated to sleep breathing disorders. Endocrinologia, Diabetes Y NutriciÓn, 2017, 64, 174-176.	0.3	0
117	Sex Hormone-Binding Globulin Reduction in Metabolic Disorders May Play a Role in NAFLD Development. Endocrinology, 2017, 158, 545-559.	2.8	38
118	Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms. Journal of Endocrinological Investigation, 2017, 40, 925-935.	3.3	33
119	Resveratrol Increases Hepatic SHBG Expression through Human Constitutive Androstane Receptor: a new Contribution to the French Paradox. Scientific Reports, 2017, 7, 12284.	3.3	16
120	Retinal Microperimetry: A New Tool for Identifying Patients With Type 2 Diabetes at Risk for Developing Alzheimer Disease. Diabetes, 2017, 66, 3098-3104.	0.6	35
121	Pulmonary Function and Sleep Breathing: Two New Targets for Type 2 Diabetes Care. Endocrine Reviews, 2017, 38, 550-573.	20.1	55
122	DNA Methylomes Reveal Biological Networks Involved in Human Eye Development, Functions and Associated Disorders. Scientific Reports, 2017, 7, 11762.	3.3	44
123	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. New England Journal of Medicine, 2017, 377, 2337-2348.	27.0	322
124	Calcium dobesilate prevents the oxidative stress and inflammation induced by diabetes in the retina of db/db mice. Journal of Diabetes and Its Complications, 2017, 31, 1481-1490.	2.3	26
125	Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia, 2017, 60, 2285-2298.	6.3	67
126	Calcium Dobesilate Prevents Neurodegeneration and Vascular Leakage in Experimental Diabetes. Current Eye Research, 2017, 42, 1273-1286.	1.5	29

#	Article	IF	CITATIONS
127	Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Project. Diabetes, 2017, 66, 2503-2510.	0.6	103
128	Serum 1,25-Dihydroxyvitamin D as a Biomarker of the Absence of Hypercalciuria in Postsurgical Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 259-266.	3.6	6
129	Diabetic macular oedema. Lancet Diabetes and Endocrinology,the, 2017, 5, 143-155.	11.4	242
130	Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial. Endocrine, 2017, 57, 83-88.	2.3	30
131	Serum Surfactant Protein D as a Biomarker for Measuring Lung Involvement in Obese Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4109-4116.	3.6	23
132	Local and Systemic Inflammatory Biomarkers of Diabetic Retinopathy: An Integrative Approach. , 2017, 58, BIO68.		103
133	Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society). Journal of Ophthalmology, 2017, 2017, 1-10.	1.3	54
134	Diabetic Retinopathy Phenotypes of Progression to Macular Edema: Pooled Analysis From Independent Longitudinal Studies of up to 2 Years' Duration. , 2017, 58, BIO206.		10
135	Type 1 diabetes: Developing the first risk-estimation model for predicting silent myocardial ischemia. The potential role of insulin resistance. PLoS ONE, 2017, 12, e0174640.	2.5	8
136	Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy., 2017, 58, 3189.		30
137	Effects of depressive symptoms on clinical outcomes, inflammatory markers and quality of life after a significant weight loss in a bariatric surgery sample. Nutricion Hospitalaria, 2017, 34, 81.	0.3	17
138	Mechanisms of retinal neuroprotection of calcium dobesilate: therapeutic implications. Neural Regeneration Research, 2017, 12, 1620.	3.0	8
139	Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes. Diabetes, 2016, 65, 172-187.	0.6	168
140	Neuroprotection as a Therapeutic Target for Diabetic Retinopathy. Journal of Diabetes Research, 2016, 2016, 1-18.	2.3	71
141	Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology. Journal of Diabetes Research, 2016, 2016, 1-13.	2.3	66
142	Gene expression profiling in hearts of diabetic mice uncovers a potential role of estrogen-related receptor $\hat{l}^3$ in diabetic cardiomyopathy. Molecular and Cellular Endocrinology, 2016, 430, 77-88.	3.2	9
143	Correlation between Retinal Vessel Calibre and Neurodegeneration in Patients with Type 2 Diabetes Mellitus in the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Ophthalmic Research, 2016, 56, 10-16.	1.9	27
144	Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naÃ-ve patients with type 2 diabetes: a pilot randomized trial. Lipids in Health and Disease, 2016, 15, 78.	3.0	103

#	Article	IF	Citations
145	Obesity Determines the Immunophenotypic Profile and Functional Characteristics of Human Mesenchymal Stem Cells From Adipose Tissue. Stem Cells Translational Medicine, 2016, 5, 464-475.	3.3	96
146	New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 1005-1007.	0.6	0
147	EndoG Knockout Mice Show Increased Brown Adipocyte Recruitment in White Adipose Tissue and Improved Glucose Homeostasis. Endocrinology, 2016, 157, 3873-3887.	2.8	15
148	Effects of the neuroprotective drugs somatostatin and brimonidine on retinal cell models of diabetic retinopathy. Acta Diabetologica, 2016, 53, 957-964.	2.5	19
149	Prevalence and Clinical Correlators of Undiagnosed Significant Depressive Symptoms Among Individuals with Type 2 Diabetes In A Mediterranean Population. Experimental and Clinical Endocrinology and Diabetes, 2016, 124, 630-636.	1.2	14
150	Nuevos tratamientos para laÂdiabetes mellitus tipoÂ2 y enfermedad cardiovascular. LaÂrevolución yaÂha empezado. Revista Espanola De Cardiologia, 2016, 69, 1005-1007.	1.2	2
151	Diabetic retinopathy. Nature Reviews Disease Primers, 2016, 2, 16012.	30.5	661
152	Modulation of microglia polarization dynamics during diabetic retinopathy in db / db mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1663-1674.	3.8	80
153	geoRge: A Computational Tool To Detect the Presence of Stable Isotope Labeling in LC/MS-Based Untargeted Metabolomics. Analytical Chemistry, 2016, 88, 621-628.	6.5	67
154	The progress in understanding and treatment of diabetic retinopathy. Progress in Retinal and Eye Research, 2016, 51, 156-186.	15.5	730
155	Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF- $^{\rm lp}$ B activity. Acta Diabetologica, 2016, 53, 109-118.	2.5	28
156	Global Assessment of the Impact of Type 2 Diabetes on Sleep through Specific Questionnaires. A Case-Control Study. PLoS ONE, 2016, 11, e0157579.	2.5	29
157	Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-NaÃ-ve Patients with Type 2 Diabetes: A Randomized Controlled Trial. PLoS ONE, 2016, 11, e0163350.	2.5	30
158	Somatostatin protects photoreceptor cells against high glucose-induced apoptosis. Molecular Vision, 2016, 22, 1522-1531.	1.1	18
159	Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology, 2015, 14, 116.	6.8	39
160	Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review. Current Medicinal Chemistry, 2015, 22, 2580-2589.	2.4	23
161	Characterization of Sleep Breathing Pattern in Patients with Type 2 Diabetes: Sweet Sleep Study. PLoS ONE, 2015, 10, e0119073.	2.5	18
162	Novel insights in SHBG regulation and clinical implications. Trends in Endocrinology and Metabolism, 2015, 26, 376-383.	7.1	210

#	Article	IF	Citations
163	Effect of glycemic control on nocturnal arterial oxygen saturation: A caseâ€control study in type 2 diabetic patients 血糖控制对åæé—´åЍè"‰è¡€æ°§é¥±å'Œåº¦çš"å½±å"ټ¼šä¸€é¡¹2型糖尿病æ,£è€…çš	5,,ç <u>-8</u> ä³⁄₄	‹å <sup>17</sup> ç…§ç"ç
164	Obesity induced by high fat diet attenuates postinfarct myocardial remodeling and dysfunction in adult B6D2F1 mice. Journal of Molecular and Cellular Cardiology, 2015, 84, 154-161.	1.9	25
165	Eating disorders are frequent among type 2 diabetic patients and are associated with worse metabolic and psychological outcomes: results from a cross-sectional study in primary and secondary care settings. Acta Diabetologica, 2015, 52, 1037-1044.	2.5	43
166	Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective <scp>E</scp> uropean <scp>E</scp> xenatide ( <scp>EUREXA</scp> ) study. Diabetes, Obesity and Metabolism, 2015, 17, 689-698.	4.4	4
167	Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?. Current Diabetes Reports, 2015, 15, 24.	4.2	14
168	Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes. Acta Diabetologica, 2015, 52, 113-122.	2.5	45
169	Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Progress in Retinal and Eye Research, 2015, 48, 160-180.	15.5	196
170	Photocoagulation of human retinal pigment epithelium <i>in vitro</i> : unravelling the effects on <scp>ARPE</scp> â€19 by transcriptomics and proteomics. Acta Ophthalmologica, 2015, 93, 348-354.	1.1	6
171	Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy. Experimental Eye Research, 2015, 140, 124-129.	2.6	26
172	SHBG-C57BL/ksJ-db/db: A New Mouse Model to Study SHBG Expression and Regulation During Obesity Development. Endocrinology, 2015, 156, 4571-4581.	2.8	23
173	Thyroid Hormone Upregulates Zinc-α2-glycoprotein Production in the Liver but Not in Adipose Tissue. PLoS ONE, 2014, 9, e85753.	2.5	11
174	The db/db Mouse: A Useful Model for the Study of Diabetic Retinal Neurodegeneration. PLoS ONE, 2014, 9, e97302.	2.5	156
175	Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus. Circulation, 2014, 129, 999-1008.	1.6	197
176	Advanced glycation end products are associated with arterial stiffness in type 1 diabetes. Journal of Endocrinology, 2014, 221, 405-413.	2.6	54
177	Oleic acid increases hepatic sex hormone binding globulin production in men. Molecular Nutrition and Food Research, 2014, 58, 760-767.	3.3	20
178	Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends in Endocrinology and Metabolism, 2014, 25, 23-33.	7.1	381
179	Glycogen storage in the human retinal pigment epithelium: a comparative study of diabetic and non-diabetic donors. Acta Diabetologica, 2014, 51, 543-552.	2.5	16
180	Adiponectin Upregulates SHBG Production: Molecular Mechanisms and Potential Implications. Endocrinology, 2014, 155, 2820-2830.	2.8	66

#	Article	IF	CITATIONS
181	Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives. Endocrine, 2014, 46, 209-214.	2.3	37
182	Ocular Anti-VEGF Therapy for Diabetic Retinopathy: The Role of VEGF in the Pathogenesis of Diabetic Retinopathy. Diabetes Care, 2014, 37, 893-899.	8.6	198
183	Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 36-44.	0.6	7
184	Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogénica. Revista Espanola De Cardiologia, 2014, 67, 36-44.	1.2	26
185	Neurodegeneration in diabetic retinopathy: Current concepts and therapeutic implications. Avances En DiabetologÃa, 2014, 30, 72-79.	0.1	2
186	Impaired endothelial function is not associated with arterial stiffness in adults with type 1 diabetes. Diabetes and Metabolism, 2013, 39, 355-362.	2.9	12
187	Mice lacking PGC- $1\hat{l}^2$ in adipose tissues reveal a dissociation between mitochondrial dysfunction and insulin resistance. Molecular Metabolism, 2013, 2, 215-226.	6.5	39
188	Identification of new pathogenic candidates for diabetic macular edema using fluorescenceâ€based difference gel electrophoresis analysis. Diabetes/Metabolism Research and Reviews, 2013, 29, 499-506.	4.0	17
189	Non-islet cell induced hypoglycemia by "big-IGF-2―in a patient with retroperitoneal solitary fibrous tumor and a papillary thyroid carcinoma: An unusual association. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2013, 60, 483-484.	0.8	3
190	Clinical spectrum of <scp>MEN2A</scp> in a large family caused by the infrequent <i><scp>RET</scp></i> mutation <scp>Cys609Phe</scp> . Clinical Genetics, 2013, 83, 384-387.	2.0	1
191	Testosterone induces cell proliferation and cell cycle gene overexpression in human visceral preadipocytes. American Journal of Physiology - Cell Physiology, 2013, 305, C355-C359.	4.6	31
192	Overexpression of Hemopexin in the Diabetic Eye. Diabetes Care, 2013, 36, 2815-2821.	8.6	14
193	Topical Administration of Somatostatin Prevents Retinal Neurodegeneration in Experimental Diabetes. Diabetes, 2013, 62, 2569-2578.	0.6	109
194	Molecular Implications of the PPARs in the Diabetic Eye. PPAR Research, 2013, 2013, 1-11.	2.4	22
195	Editorial (Hot Topics: New Insights in the Pathogenesis and Treatment of Diabetic Retinopathy). Current Medicinal Chemistry, 2013, 20, 3187-3188.	2.4	1
196	Variables Involved in the Discordance between HbA1c and Fructosamine: The Glycation Gap Revisited. PLoS ONE, 2013, 8, e66696.	2.5	19
197	Impact of Glucose-Lowering Agents on the Risk of Cancer in Type 2 Diabetic Patients. The Barcelona Case-Control Study. PLoS ONE, 2013, 8, e79968.	2.5	29
198	Genetics in Diabetic Retinopathy: Current Concepts and New Insights. Current Genomics, 2013, 14, 289-299.	1.6	62

#	Article	IF	CITATIONS
199	Fenofibrate: A New Treatment for Diabetic Retinopathy. Molecular Mechanisms and Future Perspectives. Current Medicinal Chemistry, 2013, 20, 3258-3266.	2.4	35
200	Diabetes Protects from Prostate Cancer by Downregulating Androgen Receptor: New Insights from LNCaP Cells and PAC120 Mouse Model. PLoS ONE, 2013, 8, e74179.	2.5	22
201	Somatostatin Replacement: A New Strategy for Treating Diabetic Retinopathy. Current Medicinal Chemistry, 2013, 20, 3251-3257.	2.4	17
202	Proapoptotic and survival signaling in the neuroretina at early stages of diabetic retinopathy. Molecular Vision, 2013, 19, 47-53.	1.1	39
203	Usefulness of the Vitreous Fluid Analysis in the Translational Research of Diabetic Retinopathy. Mediators of Inflammation, 2012, 2012, 1-11.	3.0	75
204	Potential Role of Tumor Necrosis Factor-α in Downregulating Sex Hormone–Binding Globulin. Diabetes, 2012, 61, 372-382.	0.6	102
205	Vitreous levels of somatostatin in patients with chronic uveitic macular oedema. Eye, 2012, 26, 1378-1383.	2.1	3
206	Update on Cardiovascular Safety of PPARgamma Agonists and Relevance to Medicinal Chemistry and Clinical Pharmacology. Current Topics in Medicinal Chemistry, 2012, 12, 585-604.	2.1	27
207	Molecular Mechanism of TNFî±-Induced Down-Regulation of SHBG Expression. Molecular Endocrinology, 2012, 26, 438-446.	3.7	50
208	IL $\hat{1}^2$ Down-regulation of Sex Hormone-Binding Globulin Production by Decreasing HNF- $4\hat{1}\pm$ Via MEK- $1/2$ and JNK MAPK Pathways. Molecular Endocrinology, 2012, 26, 1917-1927.	3.7	61
209	Arterial Stiffness Is Increased in Patients With Type 1 Diabetes Without Cardiovascular Disease. Diabetes Care, 2012, 35, 1083-1089.	8.6	70
210	Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. British Journal of Ophthalmology, 2012, 96, 1285-1290.	3.9	128
211	Non-Invasive Methods of Glucose Measurement: Current Status and Future Perspectives. Current Diabetes Reviews, 2012, 8, 48-54.	1.3	54
212	Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet, The, 2012, 379, 2270-2278.	13.7	138
213	Fenofibrate – A Potential Systemic Treatment for Diabetic Retinopathy?. American Journal of Ophthalmology, 2012, 154, 6-12.	3.3	89
214	A nontargeted proteomic approach to the study of visceral and subcutaneous adipose tissue in human obesity. Molecular and Cellular Endocrinology, 2012, 363, 10-19.	3.2	64
215	Fenofibrato en la retinopatÃa diabética: de los resultados clÃnicos al mecanismo de acción. ClÃnica E Investigación En Arteriosclerosis, 2012, 24, 29-33.	0.8	0
216	Can augmentation index substitute aortic pulse wave velocity in the assessment of central arterial stiffness in type 1 diabetes?. Acta Diabetologica, 2012, 49, 253-257.	2.5	8

#	Article	IF	CITATIONS
217	Prevention and Treatment of Diabetic Retinopathy: Evidence from Large, Randomized Trials. The Emerging Role of Fenofibrate. Reviews on Recent Clinical Trials, 2012, 7, 71-80.	0.8	24
218	Neuroprotection in Diabetic Retinopathy. Current Diabetes Reports, 2012, 12, 329-337.	4.2	59
219	Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy. Endocrine, 2012, 41, 220-226.	2.3	47
220	Proteomic Analysis of Cerebrospinal Fluid from Obese Women with Idiopathic Intracranial Hypertension: A New Approach for Identifying New Candidates in the Pathogenesis of Obesity. Journal of Neuroendocrinology, 2012, 24, 944-952.	2.6	13
221	Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. Journal of Cellular Physiology, 2012, 227, 2352-2362.	4.1	69
222	Diabetes Is the Main Factor Accounting for Hypomagnesemia in Obese Subjects. PLoS ONE, 2012, 7, e30599.	2.5	60
223	Neurodegeneration as an early event in diabetic retinopathy. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2011, 58, 211-213.	0.8	4
224	Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance. Endocrinology, 2011, 152, 4072-4079.	2.8	121
225	TNF-α system and lung function impairment in obesity. Cytokine, 2011, 54, 121-124.	3.2	17
226	Effect of atorvastatin on lipoprotein (a) and interleukin-10: A randomized placebo-controlled trial. Diabetes and Metabolism, 2011, 37, 124-130.	2.9	25
227	Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 104-110.	2.4	25
228	Erythropoietin protects retinal pigment epithelial cells against the increase of permeability induced by diabetic conditions: Essential role of JAK2/ PI3K signaling. Cellular Signalling, 2011, 23, 1596-1602.	3.6	41
229	Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin- $\hat{\Pi}^2$ by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia, 2011, 54, 1543-1553.	6.3	46
230	Metformin: a new option in cancer treatment. Clinical and Translational Oncology, 2011, 13, 363-367.	2.4	27
231	Prevalence and risk factors accounting for true silent myocardial ischemia: a pilot case-control study comparing type 2 diabetic with non-diabetic control subjects. Cardiovascular Diabetology, 2011, 10, 9.	6.8	35
232	Fenofibric Acid Reduces Fibronectin and Collagen Type IV Overexpression in Human Retinal Pigment Epithelial Cells Grown in Conditions Mimicking the Diabetic Milieu: Functional Implications in Retinal Permeability., 2011, 52, 6348.		58
233	Measuring Permeability in Human Retinal Epithelial Cells (ARPE-19): Implications for the Study of Diabetic Retinopathy. Methods in Molecular Biology, 2011, 763, 179-194.	0.9	19
234	Phagocytic Activity Is Impaired in Type 2 Diabetes Mellitus and Increases after Metabolic Improvement. PLoS ONE, 2011, 6, e23366.	2.5	160

#	Article	IF	Citations
235	LIPOPOLYSACCHARIDE-BINDING PROTEIN AND SOLUBLE CD14 IN THE VITREOUS FLUID OF PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2010, 30, 345-352.	1.7	14
236	Type 2 diabetes impairs pulmonary function in morbidly obese women: a case–control study. Diabetologia, 2010, 53, 1210-1216.	6.3	31
237	Asymptomatic Sleep-disordered Breathing in Premenopausal Women Awaiting Bariatric Surgery. Obesity Surgery, 2010, 20, 454-461.	2.1	40
238	Encephalopathy associated with autoimmune thyroid disease in patients with Graves' disease: clinical manifestations, follow-up, and outcomes. BMC Neurology, 2010, 10, 27.	1.8	69
239	Effect of intensive insulin therapy on macular biometrics, plasma VEGF and its soluble receptor in newly diagnosed diabetic patients. Diabetes/Metabolism Research and Reviews, 2010, 26, 386-392.	4.0	10
240	Insulin resistance is related to impaired lung function in morbidly obese women: a case–control study. Diabetes/Metabolism Research and Reviews, 2010, 26, 639-645.	4.0	26
241	Iron in obesity. An ancient micronutrient for a modern disease. Obesity Reviews, 2010, 11, 322-328.	6.5	77
242	Iron Overload in Diabetic Retinopathy: A Cause or a Consequence of Impaired Mechanisms?. Experimental Diabetes Research, 2010, 2010, 1-8.	3.8	37
243	Metabolic Fingerprints of Proliferative Diabetic Retinopathy: An <sup>1</sup> H-NMR–Based Metabonomic Approach Using Vitreous Humor. , 2010, 51, 4416.		88
244	The Retinal Pigment Epithelium: Something More than a Constituent of the Blood-Retinal Barrierâ€"Implications for the Pathogenesis of Diabetic Retinopathy. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-15.	3.0	337
245	Myostatin serum levels in heart failure. European Journal of Heart Failure, 2010, 12, 1379-1379.	7.1	2
246	New Pathogenic Candidates for Diabetic Macular Edema Detected By Proteomic Analysis. Diabetes Care, 2010, 33, e92-e92.	8.6	13
247	Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone. Current Drug Safety, 2010, 5, 234-244.	0.6	25
248	APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. Atherosclerosis, 2010, 209, 201-205.	0.8	38
249	Niveles séricos de miostatina en insuficiencia cardiaca crónica. Revista Espanola De Cardiologia, 2010, 63, 992-996.	1.2	17
250	Advances in the Medical Treatment of Diabetic Retinopathy. Diabetes Care, 2009, 32, 1556-1562.	8.6	124
251	Normoalbuminuric Type 1 Diabetic Patients with Retinopathy Have an Impaired Tubular Response to Desmopressin: Its Relationship with Plasma Endothelin-1. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2060-2065.	3.6	4
252	Lower Zinc-α2-Glycoprotein Production by Adipose Tissue and Liver in Obese Patients Unrelated to Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4499-4507.	3.6	95

#	Article	IF	CITATIONS
253	Gene expression of paired abdominal adipose AQP7 and liver AQP9 in patients with morbid obesity. Metabolism: Clinical and Experimental, 2009, 58, 1762-1768.	3.4	45
254	Glucose abnormalities in nonâ€elcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. Diabetes/Metabolism Research and Reviews, 2009, 25, 403-410.	4.0	26
255	Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia, 2009, 52, 2046-2055.	6.3	747
256	Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia, 2009, 52, 2633-2641.	6.3	123
257	Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema. Eye, 2009, 23, 1066-1071.	2.1	24
258	The European Exenatide study of longâ€ŧerm exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity and Metabolism, 2009, 11, 1131-1137.	4.4	7
259	Effects of high glucose concentration on the barrier function and the expression of tight junction proteins in human retinal pigment epithelial cells. Experimental Eye Research, 2009, 89, 913-920.	2.6	62
260	Apolipoprotein A1 Is Overexpressed in the Retina of Diabetic Patients. American Journal of Ophthalmology, 2009, 147, 319-325.e1.	3.3	65
261	High glucose concentration leads to differential expression of tight junction proteins in human retinal pigment epithelial cells. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2009, 56, 53-58.	0.8	21
262	Growth Factors in the Diabetic Eye. Frontiers in Diabetes, 2009, , 109-123.	0.4	1
263	Diabetes Is an Independent Risk Factor for Severe Nocturnal Hypoxemia in Obese Patients. A Case-Control Study. PLoS ONE, 2009, 4, e4692.	2.5	29
264	Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia, 2008, 51, 1574-1580.	6.3	188
265	Factors accounting for high ferritin levels in obesity. International Journal of Obesity, 2008, 32, 1665-1669.	3.4	62
266	Vascular endothelial growth factor and diabetic complications. Progress in Retinal and Eye Research, 2008, 27, 608-621.	15.5	192
267	Mitochondrial DNA oxidation and manganese superoxide dismutase activity in peripheral blood mononuclear cells from type 2 diabetic patients. Diabetes and Metabolism, 2008, 34, 117-124.	2.9	35
268	Response to Heish et al American Journal of Gastroenterology, 2008, 103, 488-488.	0.4	0
269	Expression of Erythropoietin and Its Receptor in the Human Retina. Diabetes Care, 2008, 31, 1189-1194.	8.6	93
270	Elevation of Apolipoprotein A-I and Apolipoprotein H Levels in the Vitreous Fluid and Overexpression in the Retina of Diabetic Patients. JAMA Ophthalmology, 2008, 126, 1076.	2.4	67

#	Article	IF	Citations
271	Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Molecular Vision, 2008, 14, 1496-502.	1.1	57
272	Lower Somatostatin Expression Is an Early Event in Diabetic Retinopathy and Is Associated With Retinal Neurodegeneration. Diabetes Care, 2007, 30, 2902-2908.	8.6	170
273	Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C. American Journal of Gastroenterology, 2007, 102, 2189-2195.	0.4	40
274	Deficit of Somatostatin in the Vitreous Fluid of Patients With Diabetic Macular Edema. Diabetes Care, 2007, 30, 725-727.	8.6	39
275	Fenofibrate for diabetic retinopathy. Lancet, The, 2007, 370, 1667-1668.	13.7	40
276	Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. Expert Opinion on Investigational Drugs, 2007, 16, 1209-1226.	4.1	43
277	Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology, 2007, 50, 225-231.	2.9	26
278	Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia, 2007, 50, 1294-1303.	6.3	152
279	Erythropoietin Is Expressed in the Human Retina and It Is Highly Elevated in the Vitreous Fluid of Patients With Diabetic Macular Edema. Diabetes Care, 2006, 29, 2028-2033.	8.6	124
280	Serum markers of vascular inflammation in dyslipemia. Clinica Chimica Acta, 2006, 369, 1-16.	1.1	47
281	Sustained Virological Response Correlates With Reduction in the Incidence of Glucose Abnormalities in Patients With Chronic Hepatitis C Virus Infection. Diabetes Care, 2006, 29, 2462-2466.	8.6	118
282	Intravitreous hepatocyte growth factor in patients with proliferative diabetic retinopathy: A case-control study. Diabetes Research and Clinical Practice, 2006, 71, 36-44.	2.8	25
283	Iron Deficiency in Obese Postmenopausal Women. Obesity, 2006, 14, 1724-1730.	3.0	110
284	Effect of Growth Hormone in an Experimental Model of Protein Hypercatabolism Induced by Glucocorticoids. Hormone and Metabolic Research, 2006, 38, 556-562.	1.5	1
285	Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy. Current Diabetes Reviews, 2006, 2, 71-98.	1.3	324
286	Proinflammatory Cytokines, Insulin Resistance, and Insulin Secretion in Chronic Hepatitis C patients: A case-control study. Diabetes Care, 2006, 29, 1096-1101.	8.6	81
287	Glucose Abnormalities in Patients with Hepatitis C Virus Infection: Epidemiology and pathogenesis. Diabetes Care, 2006, 29, 1140-1149.	8.6	55
288	Soluble transferrin receptors and ferritin in Type 2 diabetic patients. Diabetic Medicine, 2005, 22, 97-101.	2.3	40

#	Article	IF	CITATIONS
289	Interleukin $\hat{a} \in \mathbb{R}$ , monocyte chemoattractant protein $\hat{a} \in \mathbb{R}$ and IL $\hat{a} \in \mathbb{R}$ 0 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabetic Medicine, 2005, 22, 719-722.	2.3	164
290	Somatostatin Molecular Variants in the Vitreous Fluid: A comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care, 2005, 28, 1941-1947.	8.6	56
291	Lipoprotein(a) as a Risk Factor for Cardiovascular Mortality in Type 2 Diabetic Patients: A 10-year follow-up study. Diabetes Care, 2005, 28, 931-933.	8.6	26
292	Prevalence of mitochondrial A3243G mutation in adult type $1$ diabetic patients in Catalonia. Diabetes and Metabolism, 2005, $31$ , $621$ - $622$ .	2.9	3
293	Usefulness of Homeostasis Model Assessment for Identifying Subjects at Risk for Hypoglycemia Failure during the Insulin Hypoglycemia Test. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3408-3412.	3.6	7
294	Albumin Excretion Rate Is Not Affected by Asymptomatic Urinary Tract Infection: A prospective study. Diabetes Care, 2004, 27, 1565-1569.	8.6	12
295	Hepatocyte Growth Factor in the Vitreous Fluid of Patients With Proliferative Diabetic Retinopathy: Its relationship with vascular endothelial growth factor and retinopathy activity. Diabetes Care, 2004, 27, 287-288.	8.6	9
296	High Prevalence of Glucose Abnormalities in Patients With Hepatitis C Virus Infection: A multivariate analysis considering the liver injury. Diabetes Care, 2004, 27, 1171-1175.	8.6	183
297	Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection. Diabetes Care, 2004, 27, 2669-2675.	8.6	53
298	CD4-CD8 and CD28 Expression in T Cells Infiltrating the Vitreous Fluidin Patients With Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2004, 122, 743.	2.4	36
299	INTRAVITREOUS LEPTIN CONCENTRATIONS IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2004, 24, 30-35.	1.7	11
300	Lymphocytic hypophysitis successfully treated with azathioprine: first case report. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1581-1583.	1.9	71
301	Biological Variation of Lipoprotein(a) in a Diabetic Population. Analysis of the Causes and Clinical Implications. Clinical Chemistry and Laboratory Medicine, 2003, 41, 1075-80.	2.3	8
302	Free insulin-like growth factor $1$ in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy: a case-control study. Clinical Science, 2003, 104, 223.	4.3	21
303	Deficit of Somatostatin-Like Immunoreactivity in the Vitreous Fluid of Diabetic Patients: Possible role in the development of proliferative diabetic retinopathy. Diabetes Care, 2002, 25, 2282-2286.	8.6	58
304	Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. American Journal of Ophthalmology, 2002, 134, 376-382.	3.3	84
305	V804M RET mutation and familial medullary thyroid carcinoma: Report of a large family with expression of the disease only in the homozygous gene carriers. Surgery, 2002, 131, 509-514.	1.9	44
306	Reversible white matter alterations in encephalopathy associated with autoimmune thyroid disease. Journal of Neurology, 2002, 249, 1063-1065.	3 <b>.</b> 6	38

#	Article	IF	CITATIONS
307	Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetic Medicine, 2002, 19, 655-660.	2.3	40
308	Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: Effect of treatment with interferon. Translational Research, 2001, 137, 38-42.	2.3	48
309	Vitreous Levels of Vascular Cell Adhesion Molecule and Vascular Endothelial Growth Factor in Patients With Proliferative Diabetic Retinopathy. Diabetes Care, 2001, 24, 516-521.	8.6	108
310	Short-term hypothyroidism has no effect on serum leptin concentrations. Diabetes, Obesity and Metabolism, 2000, 2, 317-321.	4.4	11
311	Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy. British Journal of Ophthalmology, 2000, 84, 732-735.	3.9	51
312	Serum laminin as a marker of diabetic retinopathy development: a 4-year follow-up study. American Journal of Ophthalmology, 2000, 129, 347-352.	3.3	8
313	Influence of surgical stress and parenteral nutrition on serum leptin concentration. Clinical Nutrition, 2000, 19, 61-64.	5.0	31
314	Relationship Between Lipoprotein(a) Phenotypes and Plaminogen Activator Inhibitor Type $1$ in Diabetic Patients. Thrombosis Research, 2000, 99, $119-127$ .	1.7	11
315	Encephalopathy associated to autoimmune thyroid disease: a more appropriate term for an underestimated condition?. Journal of the Neurological Sciences, 2000, 176, 65-69.	0.6	113
316	Serum Concentrations of Laminin-P1 in Thrombotic Microangiopathy. Journal of the American Society of Nephrology: JASN, 2000, 11, 434-443.	6.1	5
317	Effect of panretinal photocoagulation on serum levels of laminin in patients with diabetes: a prospective study. British Journal of Ophthalmology, 1999, 83, 1056-1059.	3.9	3
318	Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Clinical Endocrinology, 1998, 49, 53-61.	2.4	94
319	Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia, 1997, 40, 1107-1109.	6.3	96
320	Serum concentrations of laminin-P1 in diabetes mellitus: usefulness as an index of diabetic microangiopathy. Diabetes Research and Clinical Practice, 1996, 32, 45-53.	2.8	7
321	High Prevalence of Hepatitis C Virus Infection in Diabetic Patients. Diabetes Care, 1996, 19, 998-1000.	8.6	253
322	Differentiated thyroid carcinoma as a cause of cervical spinal injury. Journal of Cancer Research and Clinical Oncology, 1995, 121, 189-191.	2.5	6
323	Pre-Clinical Cushing's Syndrome: Report of Three Cases and Literature Review. Hormone Research, 1994, 41, 230-235.	1.8	47
324	Adrenal abscess as a complication of adrenal fine-needle biopsy. American Journal of Medicine, 1993, 95, 244-245.	1.5	13

#	Article	IF	CITATIONS
325	EMPTY SELLA SYNDROME AND PITUITARY APOPLEXY. Lancet, The, 1988, 331, 774.	13.7	9
326	Cardiomegaly and abdominal mass in an acromegalic patient. International Journal of Cardiovascular Imaging, 1987, 2, 161-164.	0.6	0
327	Transforming growth factorâ€beta 1: A new factor reducing hepatic SHBG production in liver fibrosis. Journal of Cellular Physiology, 0, , .	4.1	1